ROBERT JONES

Professor

Cardiff University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Robert Jones is a faculty member at Cardiff University in the United Kingdom. His research focuses on the treatment of various cancers, including breast, colorectal, and prostate cancers, as demonstrated by his recent publications on combinations of innovative therapies and patient-reported outcomes. His work encompasses clinical trials and investigations into mechanisms of action for novel cancer drugs, aiming to improve survival and quality of life for patients with advanced malignancies.

Articles (10)

Year:

2025

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (10)

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM

View details

David J. Fisher

UNITED KINGDOM

View details

Louise Carter

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

View details

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

View details

Debashis Sarker

King’s College London

UNITED KINGDOM

View details

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

View details

Richard Wilson

Professor of GI Oncology

University of Glasgow

UNITED KINGDOM

View details

Elena Garralda

SPAIN

View details

Angela Casbard

UNITED KINGDOM

View details

Zsolt Horváth

Head of Department

Bács-Kiskun County Hospital

HUNGARY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ROBERT JONES

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Inhibition of WEE1 Is Effective in <i>TP53</i>- and <i>RAS</i>-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring.

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer

Collaborators (10)

Patricia Roxburgh

David J. Fisher

Louise Carter

Rebecca S. Kristeleit

Debashis Sarker

Ruth Plummer

Richard Wilson

Elena Garralda

Angela Casbard

Zsolt Horváth

Make your next move.